论文部分内容阅读
目的研究胰腺癌组织中E26转录因子1(ETS-1)、p53、血管内皮生长因子(VEGF)、表皮生长因子受体(EGFR)、人类表皮生长因子受体2(HER-2)和环氧化酶2(COX-2)的蛋白表达及其与胰腺癌临床病理学特征的相关性。方法收集40例胰腺癌患者组织标本,免疫组化SP法检测肿瘤组织中各蛋白表达水平。分析ETS-1蛋白表达与患者临床病理学特征的相关性和ETS-1蛋白表达与p53、VEGF、EGFR、HER-2、COX-2蛋白表达之间的相关性。结果ETS-1、p53、VEGF、EGFR、HER-2、COX-2蛋白在胰腺癌组织中阳性表达率分别为65.0%、60.0%、37.5%、62.5%、37.5%、55.0%。ETS-1蛋白表达水平越高,脉管内癌栓发生率越高,肿瘤分期越晚(P<0.05)。胰腺癌中ETS-1蛋白呈高表达时,p53、COX-2蛋白也呈高表达状态(P<0.05)。结论胰腺癌组织中存在ETS-1、p53、VEGF、EGFR、HER-2、COX-2蛋白表达。ETS-1高表达的胰腺癌患者肿瘤分期晚,预后差。ETS-1蛋白高表达促胰腺癌发生发展机制可能与p53、COX-2蛋白高表达相关。
Objective To investigate the expression of ETS-1, p53, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER-2) Expression of COX-2 protein and its correlation with clinicopathological features of pancreatic cancer. Methods Tissue samples of 40 patients with pancreatic cancer were collected. The expression of each protein in tumor tissues was detected by immunohistochemical SP method. The correlation between the expression of ETS-1 protein and clinicopathological characteristics of patients and the correlation between ETS-1 protein expression and p53, VEGF, EGFR, HER-2 and COX-2 protein expression were analyzed. Results The positive rates of ETS-1, p53, VEGF, EGFR, HER-2 and COX-2 in pancreatic cancer tissues were 65.0%, 60.0%, 37.5%, 62.5%, 37.5% and 55.0%, respectively. The higher the level of ETS-1 protein expression, the higher the incidence of intravascular thrombosis and the later the tumor staging (P <0.05). When ETS-1 protein was highly expressed in pancreatic cancer, the expression of p53 and COX-2 protein were also high (P <0.05). Conclusions The expression of ETS-1, p53, VEGF, EGFR, HER-2 and COX-2 in pancreatic cancer tissues were significantly different. ETS-1-overexpressing pancreatic cancer patients had a late-stage tumor with poor prognosis. ETS-1 protein overexpression may contribute to the pathogenesis of pancreatic cancer and p53, COX-2 protein overexpression.